



TFF Pharmaceuticals Announces Results of Its 2020 Annual Meeting of Stockholders

September 30, 2020

AUSTIN, Texas--(BUSINESS WIRE)--Sep. 30, 2020-- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the results from its Annual Meeting of Stockholders, which took place virtually earlier today. All director nominees were elected to the Board of Directors and Marcum LLP was appointed as the Company's independent registered public accounting firm for the 2020 fiscal year. A total of 18,076,265 common shares (representing approximately 83% of all issued and outstanding common shares of TFF) were represented at the meeting.

The detailed results of the Annual Meeting were as follows:

1. Election of Directors

All eight (8) nominees for the Board of Directors that were proposed by TFF's management were elected as a Director of the Company. All the nominated directors were members of the Board of Directors of TFF prior to today's Meeting. The votes were cast for each nominee as follows:

<u>Nominee</u>	<u>Yes</u>	<u>Withheld</u>
Aaron Fletcher, Ph.D.	11,253,545	28,609
Brian Windsor, Ph.D.	11,253,543	28,611
Stephen C. Rocamboli	11,253,546	28,608
Randy Thurman	11,253,545	28,609
Glenn Mattes	11,253,543	28,611
Robert S. Mills	11,094,669	187,485
Harlan Weisman, M.D.	11,183,280	98,874
Malcolm Fairbairn	11,253,504	28,650

2. Appointment of Auditor

Marcum LLP was appointed as the Company's independent registered public accounting firm for the 2020 fiscal year. The votes were cast as follows:

<u>Yes</u>	<u>No</u>	<u>Abstain</u>
18,058,701	8,545	9,019

Virtual Webcast

Due to recommendations from local authorities and ongoing concerns regarding the spread of the novel coronavirus (COVID-19), TFF held its Annual Meeting entirely by webcast, to prioritize the safety and health of its stockholders, employees and other stakeholders.

About TFF Pharmaceuticals' Thin Film Freezing technology platform

TFF Pharmaceuticals' Thin Film Freezing (TFF) platform was designed to improve the solubility and absorption of poorly water-soluble drugs and is particularly suited to generate dry powder particles with properties targeted for inhalation delivery, especially to the deep lung, an area of extreme interest in respiratory medicine. The TFF process results in a "Brittle Matrix Particle," which possesses low bulk density, high surface area, and typically an amorphous morphology, allowing the particles to supersaturate when contacting the target site, such as lung tissue. Based upon laboratory experiments the aerodynamic properties of the particles are such that the portion of a drug deposited to the deep lung has the potential to reach as high as 75 percent.

About TFF Pharmaceuticals

TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing, or TFF, technology platform. Early testing confirms that the TFF platform can significantly improve the solubility and absorption of poorly water-soluble drugs, a class of drugs that comprises approximately one-third of the major pharmaceuticals worldwide, thereby improving their pharmacokinetics. TFF Pharmaceuticals has two lead drug candidates: Voriconazole Inhalation Powder and Tac-Lac Inhalation Powder. The Company plans to add to this pipeline by collaborating with large pharmaceutical partners. The TFF Platform is protected by 42 patents issued or pending in the US and internationally. To learn more about TFF Pharmaceuticals and its product candidates, visit the Company's website at <https://tffpharma.com>.

SAFE HARBOR

This press release contains forward-looking statements regarding TFF Pharmaceuticals, Inc., including the benefits of the Company's TFF platform and the dry powder version of remdesivir and the Company's plans to add to its existing pipeline of product candidates. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors

are: (i) the risk that the Company may be unable to successfully conclude clinical testing or obtain pre-market approval of its dry powder versions of Voriconazole and Tacrolimus, (ii) no drug product incorporating the TFF platform has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (iii) the Company has no current agreements or understandings with any large pharmaceutical companies for the development of a drug product incorporating the TFF Platform, (iv) the risk that the Company will not be able to conclude a long-term commercial agreement with any third-party, and (v) those other risks disclosed in the section "Risk Factors" included in the Company's Registration Statement on Form S-1 filed with the SEC on September 9, 2020. TFF Pharmaceuticals cautions readers not to place undue reliance on any forward-looking statements. TFF Pharmaceuticals does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200930005955/en/): <https://www.businesswire.com/news/home/20200930005955/en/>

Company Contacts:

Glenn Mattes
President and CEO
TFF Pharmaceuticals, Inc.
gmattes@tffpharma.com
737-802-1973

Kirk Coleman
Chief Financial Officer
TFF Pharmaceuticals, Inc.
kcoleman@tffpharma.com
817-989-6358

Investor Relations and Media Contact:

Paul Sagan
LaVoieHealthScience
psagan@lavoiehealthscience.com
617-953-4779

Source: TFF Pharmaceuticals, Inc.